The microbiome in cancer patients treated with immune-checkpoint inhibitor

The microbiome in cancer patients treated with immune-checkpoint inhibitor - The microbiome in cancer patients treated with immune-checkpoint inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023303

Enrollment

Registered

2016-08-01

Start date

2016-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically proven carcinoma 2) Aged 20 years old or more 3) metastatic or advanced disease 4) planing immune-checkpoint inhibitor 5) No need for previous treatment 6) Written informed consent

Exclusion criteria

Exclusion criteria: Patients whom principle/sub-investigator judged ineligible to participate in this study.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
response rate, progression-free survival, disease control rate, toxicity	—

Countries

Japan

Contacts

Public ContactMotoo Nomura

Kyoto university Department of Therapeutic Oncology

excell@hkg.odn.ne.jp075-751-3518

Outcome results